Q4 2026 Gland Pharma Ltd Earnings Call Transcript
Key Points
- Gland Pharma Ltd (NSE:GLAND) reported a strong quarter with revenues of INR 17,428 million, reflecting a 22% year-on-year growth.
- The company achieved an adjusted EBITDA margin of 30% for the quarter, showcasing significant profitability improvements.
- The CDMO business represented 46% of total revenues, driven by a healthy growth of 28%, highlighting its strategic focus on this segment.
- Gland Pharma Ltd (NSE:GLAND) launched 31 products in the US during the year, contributing to strong revenue growth.
- The company is investing in capacity expansions with a CapEx outlay of Rs. 2000 crores over the next five years to cater to increased demand.
- The company's effective tax rate for the year stood at approximately 29%, which could impact net profitability.
- There is inherent quarter-to-quarter variability in the performance of the ChenXi business, which could affect overall financial stability.
- The company faces challenges in providing guidance for GLP-1 products due to uncertainties in market approvals and volumes.
- Gland Pharma Ltd (NSE:GLAND) is experiencing some impact from geopolitical tensions in the Middle East, affecting shipments and revenue from that region.
- The integration of Synexi with Gland Pharma's core operations is still in progress, which may delay realizing full synergies and benefits.
Ladies and Gentlemen, Good day and welcome to the Gland Pharma Limited Q4 FY26 Earnings Conference Call.
As a reminder, all participant lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
Should you need assistance during this conference call, please signal an operator by pressing and then 0 on your touch-tone phone.
Please note that this conference is being recorded.
I now hand the conference over to Mr. Srinivas Dangir, Head of Investor Relations.
Thank you, and over to you, sir.
So thank you, Sagar.
Good evening everyone. We welcome you to Gland Pharma Earnings Conference Call for Q4 of FY26. I am Srinivas Dange from the Investor Relations Team at Gland Pharma. Today we have Mr. Srinivas Sadhu, Executive Chairman, Mr. Ravi Mitra, Chief Financial Officer from India office, and Mr. Allan, CEO of Senexi, who is connected from France. We will begin the call with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
